Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional chinese herbal formula: A multicenter, randomized, open label clinical trial

mBio

Volumn 9, Issue 3, 2018, Pages

  Tong, Xiaolin ^a   Xu, Jia ^b   Lian, Fengmei ^a   Yu, Xiaotong ^a,c   Zhao, Yufeng ^d   Xu, Lipeng ^a   Zhang, Menghui ^b   Zhao, Xiyan ^a,c   Shen, Jian ^d   Wu, Shengping ^a,c   Pang, Xiaoyan ^b   Tian, Jiaxing ^a,c   Zhang, Chenhong ^b   Zhou, Qiang ^a   Wang, Linhua ^b   Pang, Bing ^a   Chen, Feng ^b   Peng, Zhiping ^a   Wang, Jing ^b   Zhen, Zhong ^a   Fang, Chao ^b   Li, Min ^a   Chen, Limei ^b   Zhao, Liping ^b,d   more..

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b Shanghai Jiao Tong University   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Clinical trial; Gut microbiota; Hyperlipidemia; Metformin; Traditional Chinese medicine; Type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYPERGLYCEMIC AGENT; INSULIN; LIPID; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; RNA 16S; TRIACYLGLYCEROL; ANTIOBESITY AGENT; HERBACEOUS AGENT;

ARTICLE; BLAUTIA; CHINESE MEDICINE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FAECALIBACTERIUM; GENE SEQUENCE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE FLORA; LIPID HOMEOSTASIS; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; ADOLESCENT; ADULT; AGED; BACTERIUM; BLOOD; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BACTERIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; HYPERLIPIDEMIAS; MALE; METFORMIN; MIDDLE AGED; TRIGLYCERIDES; YOUNG ADULT;

EID: 85047508572     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02392-17     Document Type: Article

References (56)

1. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, Hirst M, Hwang C, Magliano D, Patterson C, Scott C, Shaw J, Soltesz G, Usher-Smith J, Whiting D. 2013, IDF diabetes atlas, 6th ed. International Diabetes Federation, Basel, Switzerland.
2. Kahn SE, Cooper ME, Del Prato S. 2014. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068-1083. https://doi.org/10.1016/S0140-6736(13)62154-6.
3. Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107. https://doi.org/10.1038/nri2925.
4. Hotamisligil GS. 2008. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes 32(Suppl 7):S52-S54. https://doi.org/10.1038/ijo.2008.238.
5. Shoelson SE, Goldfine AB. 2009. Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med 15:373-374. https://doi.org/10.1038/nm0409-373.
6. Zhao L. 2013. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 11:639-647. https://doi.org/10.1038/nrmicro3089.
7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-1031. https://doi.org/10.1038/nature05414.
8. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. 2010. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:228-231. https://doi.org/10.1126/science.1179721.
9. Fei N, Zhao L. 2013. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 7:880-884. https://doi.org/10.1038/ismej.2012.153.
10. Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, Zhang M, Wang L, Hou Y, Ouyang H, Zhang Y, Zheng Y, Wang J, Lv X, Wang Y, Zhang F, Zeng B, Li W, Yan F, Zhao Y, Pang X, Zhang X, Fu H, Chen F, Zhao N, Hamaker BR, Bridgewater LC, Weinkove D, Clement K, Dore J, Holmes E, Xiao H, Zhao G, Yang S, Bork P, Nicholson JK, Wei H, Tang H, Zhang X, Zhao L. 2015. Dietary modulation of gut microbiota contributes to alleviation of both genetic and simple obesity in children. EBioMedicine 2:968-984. https://doi.org/10.1016/j.ebiom.2015.07.007.
11. Pruski M, Krysiak R, Okopien B. 2009. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 32:1421-1424. https://doi.org/10.2337/dc08-2335.
12. Luong DQ, Oster R, Ashraf AP. 2015. Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. J Pediatr Endocrinol Metab 28:649-655. https://doi.org/10.1515/jpem-2014-0201.
13. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, Walser M, Samà M, Aimaretti G, Isgaard J, Saccà L. 2012. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 61:944-953. https://doi.org/10.2337/db11-1132.
14. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE. 2009. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137: 635-646. https://doi.org/10.1016/j.cell.2009.03.016.
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. https://doi.org/10.1172/JCI13505.
16. Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, Zavaroni I, Coscelli C, Butturini U. 1984. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin 9:47-51. https://doi.org/10.1185/03007998409109558.
17. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. 2014. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727-735. https://doi.org/10.1136/gutjnl-2012-303839.
18. Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X, Zhao L. 2015. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 5:14405. https://doi.org/10.1038/srep14405.
19. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jorgensen T, Levenez F, Dore J, MetaHIT Consortium, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. 2015. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262-266. https://doi.org/10.1038/nature15766.
20. Xu J, Lian F, Zhao L, Zhao Y, Chen X, Zhang X, Guo Y, Zhang C, Zhou Q, Xue Z, Pang X, Zhao L, Tong X. 2015. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 9:552-562. https://doi.org/10.1038/ismej.2014.177.
21. Han J, Yang N, Zhang F, Zhang C, Liang F, Xie W, Chen W. 2015. Rhizoma Anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents. J Ethnopharmacol 172:368-376. https://doi.org/10.1016/j.jep.2015.05.016.
22. Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, Ingkaninan K, Plianbangchang P, Haines ST. 2011. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 134:422-428. https://doi.org/10.1016/j.jep.2010.12.045.
23. Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK. 2003. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88:107-111. https://doi.org/10.1016/S0378-8741(03)00184-3.
24. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559-2565. https://doi.org/10.1210/jc.2007-2404.
25. Choi HC, Kim SJ, Son KY, Oh BJ, Cho BL. 2013. Metabolic effects of aloe vera gel complex in obese prediabetes and early non-treated diabetic patients: randomized controlled trial. Nutrition 29:1110-1114. https://doi.org/10.1016/j.nut.2013.02.015.
26. Kim K, Kim H, Kwon J, Lee S, Kong H, Im SA, Lee YH, Lee YR, Oh ST, Jo TH, Park YI, Lee CK, Kim K. 2009. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulindependent diabetes mellitus. Phytomedicine 16:856-863. https://doi.org/10.1016/j.phymed.2009.02.014.
27. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. 2009. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150:830-839, W147-W149. https://doi.org/10.7326/0003-4819-150-12-200906160-00006.
28. Verhoeven V, Van der Auwera A, Van Gaal L, Remmen R, Apers S, Stalpaert M, Wens J, Hermans N. 2015. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind, placebo controlled randomized trial. BMC Complement Altern Med 15:52. https://doi.org/10.1186/s12906-015-0576-9.
29. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, Li X, Ning G, Zhao L. 2012. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 7:e42529. https://doi.org/10.1371/journal.pone.0042529.
30. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. 2004. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1-14. https://doi.org/10.1111/j.1365-2796.2004.01328.x.
31. Baxter NT, Zackular JP, Chen GY, Schloss PD. 2014. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2:20. https://doi.org/10.1186/2049-2618-2-20.
32. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J. 2011. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141:1782-1791. https://doi.org/10.1053/j.gastro.2011.06.072.
33. Duca FA, Sakar Y, Lepage P, Devime F, Langelier B, Doré J, Covasa M. 2014. Replication of obesity and associated signaling pathways through transfer of microbiota from obese-prone rats. Diabetes 63:1624-1636. https://doi.org/10.2337/db13-1526.
34. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ. 2002. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol 52:1615-1620. https://doi.org/10.1099/00207713-52-5-1615.
35. Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. 2002. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol 52:2141-2146. https://doi.org/10.1099/00207713-52-6-2141.
36. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet J-P, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731-16736. https://doi.org/10.1073/pnas.0804812105.
37. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L. 2008. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 105:2117-2122. https://doi.org/10.1073/pnas.0712038105.
38. Martín R, Miquel S, Chain F, Natividad JM, Jury J, Lu J, Sokol H, Theodorou V, Bercik P, Verdu EF, Langella P, Bermúdez-Humarán LG. 2015. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol 15:67. https://doi.org/10.1186/s12866-015-0400-1.
39. Rossi O, Khan MT, Schwarzer M, Hudcovic T, Srutkova D, Duncan SH, Stolte EH, Kozakova H, Flint HJ, Samsom JN, Harmsen HJ, Wells JM. 2015. Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS One 10:e0123013. https://doi.org/10.1371/journal.pone.0123013.
40. Miquel S, Leclerc M, Martin R, Chain F, Lenoir M, Raguideau S, Hudault S, Bridonneau C, Northen T, Bowen B, Bermúdez-Humarán LG, Sokol H, Thomas M, Langella P. 2015. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio 6:e00300-15. https://doi.org/10.1128/mBio.00300-15.
41. Quévrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermúdez-Humarán LG, Pigneur B, Lequin O, Kharrat P, Thomas G, Rainteau D, Aubry C, Breyner N, Afonso C, Lavielle S, Grill JP, Chassaing G, Chatel JM, Trugnan G, Xavier R, Langella P, Sokol H, Seksik P. 2016. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65:415-425. https://doi.org/10.1136/gutjnl-2014-307649.
42. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. 2013. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99-103. https://doi.org/10.1038/nature12198.
43. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55-60. https://doi.org/10.1038/nature11450.
44. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. 2013. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 8:e71108. https://doi.org/10.1371/journal.pone.0071108.
45. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K. 2010. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049-3057. https://doi.org/10.2337/db10-0253.
46. Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. 2012. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem 23:51-59. https://doi.org/10.1016/j.jnutbio.2010.10.008.
47. Park SK, Kim MS, Bae JW. 2013. Blautia faecis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 63:599-603. https://doi.org/10.1099/ijs.0.036541-0.
48. Park SK, Kim MS, Roh SW, Bae JW. 2012. Blautia stercoris sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 62:776-779. https://doi.org/10.1099/ijs.0.031625-0.
49. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, Queipo-Ortuño MI. 2013. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 11:46. https://doi.org/10.1186/1741-7015-11-46.
50. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR. 2015. Intestinal Blautia is associated with reduced death from graft-versushost disease. Biol Blood Marrow Transplant 21:1373-1383. https://doi.org/10.1016/j.bbmt.2015.04.016.
51. Na L, Zhang Q, Jiang S, Du S, Zhang W, Li Y, Sun C, Niu Y. 2015. Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. Sci Rep 5:10344. https://doi.org/10.1038/srep10344.
52. Sanugul K, Akao T, Li Y, Kakiuchi N, Nakamura N, Hattori M. 2005. Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond. Biol Pharm Bull 28:1672-1678. https://doi.org/10.1248/bpb.28.1672.
53. Zhang Q, Wu Y, Wang J, Wu G, Long W, Xue Z, Wang L, Zhang X, Pang X, Zhao Y, Zhao L, Zhang C. 2016. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium. Sci Rep 6:27572. https://doi.org/10.1038/srep27572.
54. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26:2460-2461. https://doi.org/10.1093/bioinformatics/btq461.
55. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-336. https://doi.org/10.1038/nmeth.f.303.
56. Friedman J, Alm EJ. 2012. Inferring correlation networks from genomic survey data. PLoS Comput Biol 8:e1002687. https://doi.org/10.1371/journal.pcbi.1002687.